Long-term health-related quality of life after curative treatment for prostate cancer: A regional cross-sectional comparison of two standard treatment modalities

被引:5
作者
Hjalm-Eriksson, Marie [1 ,2 ]
Lennernas, Bo [3 ]
Ullen, Anders [1 ,2 ]
Johansson, Hemming [1 ]
Hugosson, Jonas [4 ]
Nilsson, Sten [1 ,2 ]
Brandberg, Yvonne [1 ]
机构
[1] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden
[2] Karolinska Univ Hosp, Dept Oncol, SE-17176 Stockholm, Sweden
[3] Sahlgrens Univ Hosp, Jubileumskliniken, Gothenburg, Sweden
[4] Sahlgrens Univ Hosp, Dept Urol, Gothenburg, Sweden
关键词
prostate cancer; health-related quality of life; prostatectomy; external beam radiotherapy; HDR-brachytherapy; EXTERNAL-BEAM RADIOTHERAPY; RATE BRACHYTHERAPY BOOST; RADICAL PROSTATECTOMY; OUTCOMES; THERAPY; QLQ-C30; RISK;
D O I
10.3892/ijo.2014.2734
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Effects on long-term health-related quality of life (HRQoL) were evaluated in patients treated for localized prostate cancer by two standard modalities: radical retropubic prostatectomy (RP) and external beam radiotherapy combined with a high-dose-rate brachytherapy boost (HDRBT-EBRT). The HRQoL data were compared with age-adjusted normative data. Men diagnosed with localized prostate cancer and treated with curative intent in Gothenburg, Sweden, 1988-1997 were included. HRQoL was measured in October 2000 using the EORTC QLQ-C30 and EORTC QLQ-PR25 questionnaires, with a response rate of 82% (n=347). No differences in patient characteristics were found between the two treatment groups, except regarding tumor stage and PSA recurrence at the time of the questionnaires. In the RP group, 42% had T1 and 6% had T3-4 tumors; corresponding proportions in the HDRBT-EBRT group were 29% and 13% (P=0.01). PSA recurrence was detected in 44% of RP patients and 9% of HDRBT-EBRT patients. In most domains, mean HRQoL scores were high and similar to the scores for the age-adjusted normative sample. However, patients reported better role and physical function compared to the normal population. We also observed more sleeping disturbances but less pain among patients than in the normal population. The disease-specific questionnaires showed statistically significant higher levels of bowel and urinary problems in the irradiated group than in the RP group, and the absolute difference between the groups was small and had minor clinical significance. We conclude that overall the general quality of life was rated high by the patients irrespective of curative treatment modality and in agreement with age-adjusted normative data. Statistically significant differences in bowel and urinary symptoms were found between the two treatment groups in favor of the RP group, but the clinical significance was small.
引用
收藏
页码:381 / 388
页数:8
相关论文
共 22 条
  • [1] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY
    AARONSON, NK
    AHMEDZAI, S
    BERGMAN, B
    BULLINGER, M
    CULL, A
    DUEZ, NJ
    FILIBERTI, A
    FLECHTNER, H
    FLEISHMAN, SB
    DEHAES, JCJM
    KAASA, S
    KLEE, M
    OSOBA, D
    RAZAVI, D
    ROFE, PB
    SCHRAUB, S
    SNEEUW, K
    SULLIVAN, M
    TAKEDA, F
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) : 365 - 376
  • [2] American Joint Committee on Cancer, 1992, MANUAL STAGING CANC
  • [3] Fayers P, 2001, The EORTC QLQ-C30 scoring manual, V3rd
  • [4] An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer
    Frank, Steven J.
    Pisters, Louis L.
    Davis, John
    Lee, Andrew K.
    Bassett, Roland
    Kuban, Deborah A.
    [J]. JOURNAL OF UROLOGY, 2007, 177 (06) : 2151 - 2156
  • [5] LAPAROSCOPIC OBTURATOR LYMPH-NODE DISSECTION IN PATIENTS WITH PROSTATIC-CANCER
    GRENABO, L
    GRUNDTMAN, S
    HEDELIN, H
    [J]. SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 1995, 29 (01): : 51 - 55
  • [6] Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group
    Grimm, Peter
    Billiet, Ignace
    Bostwick, David
    Dicker, Adam P.
    Frank, Steven
    Immerzeel, Jos
    Keyes, Mira
    Kupelian, Patrick
    Lee, W. Robert
    Machtens, Stefan
    Mayadev, Jyoti
    Moran, Brian J.
    Merrick, Gregory
    Millar, Jeremy
    Roach, Mack
    Stock, Richard
    Shinohara, Katsuto
    Scholz, Mark
    Weber, Ed
    Zietman, Anthony
    Zelefsky, Michael
    Wong, Jason
    Wentworth, Stacy
    Vera, Robyn
    Langley, Stephen
    [J]. BJU INTERNATIONAL, 2012, 109 : 22 - 29
  • [7] Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls
    Hoffman, RM
    Gilliland, FD
    Penson, DF
    Stone, SN
    Hunt, WC
    Potosky, AL
    [J]. CANCER, 2004, 101 (09) : 2011 - 2019
  • [8] Hugosson J, 1996, EUR UROL, V29, P413
  • [9] Analysis of health related quality of life (HRQoL) of patients with clinically localized prostate cancer, one year after treatment with external beam radiotherapy (EBRT) alone versus EBRT and high dose rate brachytherapy (HDRBT)
    Joseph, Kurian Jones
    Alvi, Riaz
    Skarsgard, David
    Tonita, Jon
    Pervez, Nadeem
    Small, Cormac
    Tai, Patricia
    [J]. RADIATION ONCOLOGY, 2008, 3 (1)
  • [10] EXTERNAL-BEAM RADIOTHERAPY OF LOCALIZED PROSTATIC ADENOCARCINOMA - EVALUATION OF CONFORMAL THERAPY, FIELD NUMBER AND TARGET MARGINS
    LENNERNAS, B
    RIKNER, G
    LETOCHA, H
    NILSSON, S
    [J]. ACTA ONCOLOGICA, 1995, 34 (07) : 953 - 958